June 2015 - 26 articles
Background: The endpoints of progression-free survival (pfs) and time-to-progression (ttp) are frequently used to evaluate the clinical benefit of anticancer drugs. However, the surrogacy of those endpoints for overall survival (os) is not validated...
Current Oncology has made great strides over the years to improve the quality, success, and sustainability of our renowned journal. [...]
About the ongoing breast cancer screening mammography debate (less a controversy, because many points of consensus and convergence are present if not always apparent), we can make these points as prelude: that it is complex; that it is naïvely implau...
BACKGROUND [...]
In the Canadian National Breast Screening Study, the hazard ratio for breast cancer–specific death was 1.47 for women with cancers detected in the prevalence screening round, 0.9 for women with cancers detected in the subsequent four screening rounds...
There is a clear evidence-to-practice gap in bladder cancer care. [...]
Physicians receive many online survey requests from both academic and pharmaceutical sources [...]
Introduction: Randomized controlled trials (RCTS) are the “gold standard” for establishing treatment efficacy; however, efficacy does not automatically translate to a comparable level of effectiveness in routine practice. Our objectives were to (1) d...
Background: Proliferative scoring of breast tumours can guide treatment recommendations, particularly for estrogen receptor (ER)–positive, HER2-negative, T1–2, N0 disease. Our objectives were to (1) estimate the proportion of such patients for whom p...
Introduction: The purpose of the present study was to investigate the efficacy of an ondansetron rapidly dissolving film (RDF) in the prophylaxis of radiation-induced nausea and vomiting (RINV). Rapidly dissolving film formulations facilitate drug de...
of 3
